Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 1, 2010, Pages 614-618

  Lee, Hyang Ae ^a   Kim, Eun Joo ^a   Hyun, Sung Ae ^a   Park, Sung Gurl ^a   Kim, Ki Suk ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; LAPATINIB; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; POTASSIUM ION; ANTINEOPLASTIC AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL; ION CHANNEL; KCNE1 PROTEIN, HUMAN; KCNJ2 PROTEIN, HUMAN; KCNQ1 PROTEIN, HUMAN; MUSCLE PROTEIN; POTASSIUM CHANNEL HERG; QUINAZOLINE DERIVATIVE; SCN5A PROTEIN, HUMAN; SCN5A PROTEIN, RAT; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CALCIUM CURRENT; CHANNEL GATING; CONTROLLED STUDY; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; HUMAN CELL; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE FIBER; RABBIT; SODIUM CURRENT; ACTION POTENTIAL; ANIMAL; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EMBRYOLOGY; GENETIC TRANSFECTION; HEART MUSCLE CONDUCTION SYSTEM; KIDNEY; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY;

ORYCTOLAGUS CUNICULUS; RATTUS;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART CONDUCTION SYSTEM; HUMANS; ION CHANNELS; KCNQ1 POTASSIUM CHANNEL; KIDNEY; MUSCLE PROTEINS; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, INWARDLY RECTIFYING; POTASSIUM CHANNELS, VOLTAGE-GATED; PURKINJE FIBERS; QUINAZOLINES; RABBITS; SODIUM CHANNELS; TRANSFECTION;

EID: 77953819421     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00556.x     Document Type: Article

References (25)

1. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004 9 : 10 5.
2. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001 1 : 85 94.
3. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of the EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002 21 : 6255 6263.
4. Petrov KG, Zhang YM, Carter M, Cockerill GS, Dickerson S, Gauthier CA et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg Med Chem Lett 2006 16 : 4686 4691.
5. Clien KR. Stress pathways and heart failure. Cell 1999 98 : 555 558.
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002 8 : 459 465.
7. Burris HA III., Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005 23 : 5305 5313.
8. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008 83 : 679 686.
9. Barry DM, Xu H, Schuessler RB, Nerbonne JM. Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 alpha subunit. Circ Res 1998 83 : 560 567.
10. Jeron A, Mitchell GF, Zhou J, Murata M, London B, Buckett P et al. Inducible polymorphic ventricular tachyarrhythmias in a transgenic mouse model with a long Q-T phenotype. Am J Physiol Heart Circ Physiol 2000 278 : 1891 1898.
11. Bosch RF, Gaspo R, Busch AE, Lang HJ, Li GR, Nattel S. Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovas Res 1998 38 : 441 450.
12. Lu Z, Kamiya K, Opthof T, Yasui K, Kodama I. Density and kinetics of I(Kr) and I(Ks) in guinea pig and rabbit ventricular myocytes explain different efficacy of I(Ks) blockade at high heart rate in guinea pig and rabbit: implications for arrhythmogenesis in humans. Circulation 2001 104 : 951 956.
13. Nakashima H, Gerlach U, Schmidt D, Nattel S. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res 2004 61 : 705 714.
14. Gross GJ. IK1: the long and the short QT of it. Heart Rhythm. 2006 3 : 336 338.
15. Saldeen J, Curiel DT, Eizirik DL, Andersson A, Strandell E, Buschard K et al. Efficient gene transfer to dispersed human pancreatic islet cells in vitro using adenovirus-polylysine/DNA complexes or polycationic liposomes. Diabetes 1996 45 : 1197 1203.
16. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981 391 : 85 100.
17. + current by primaquine. Br J Pharmacol 2002 135 : 751 763.
18. Fukyama O. Nicardipine, a new calcium channel blocker: role for vascular selectivity. Clin Cardiol 1989 12 : A11.
19. Schram G, Pourrier M, Wang Z, White M, Nattel S. Barium block of Kir2 and human cardiac inward rectifier currents: evidence for subunit-heteromeric contribution to native currents. Cardiovasc Res 2003 59 : 328 338.
20. Brown AM, Rampe D. Drug-induced long QTsyndrome: is HERG the root of all evil? Pharm News 2000 7 : 15 20.
21. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995 81 : 299 307.
22. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995 80 : 795 803.
23. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 440 : 463 469.
24. Bence AK, Anderson EB, Halepota MA, Doukas MA, DeSimone PA, Davis GA. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 2005 23 : 39 49.
25. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990 96 : 195 215.